Finerenone, a selective non-steroidal MR antagonist, also caused an initial eGFR decrease and decreased CKD progression and improved cardiovascular outcomes in patients with type 2 DM and CKD [40]. The gene discussed is NR3C2; the disease is chronic kidney disease.